Trial · NCT06772272
Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.
NCT06772272, Phase 3, Active not recruiting, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery. Trials, record NCT06772272. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06772272
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.
- NCT number
- NCT06772272
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 158 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- Perioperative Anemia
- Interventions
- Roxadustat
- First posted
- 2025-01-13
- Last updated
- 2025-01-13
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Perioperative RBC transfusion requirement | Discharge or within 4 weeks of hospitalization (whichever comes first) | The incidence of the composite outcome of perioperative transfusion requirement (defined as the occurrence of one or more of the following events): * Red blood cell transfusion * Perioperative lowest hemoglobin level below 80 g/L |
| Secondary | Blood Transfusion Rate | Discharge or within 4 weeks of hospitalization (whichever comes first) | The percentage of participants in each group requiring red blood cell transfusion during the perioperative period. |
| Secondary | Volume of Blood Transfused | Discharge or within 4 weeks of hospitalization (whichever comes first) | The total volume of red blood cells transfused in units per participant during the perioperative period. |
| Secondary | Hemoglobin Levels at Different Time Points | Baseline, pre-surgery, during surgery, 1, 3, 5, and 28 days post-surgery, and at 1 month and 6 months follow-up. | Hemoglobin levels will be measured at key time points to assess changes, including: at baseline (enrollment), pre-surgery, during surgery, at 1, 3, 5, 28 days post-surgery, and at 1 month and 6 months follow-up visits to monitor longer-term effects. |
| Secondary | Ferritin and Anemia-Related Blood Tests | Baseline, pre-surgery, 1, 3, 5, 28 days post-surgery. | Levels of ferritin and other biomarkers related to anemia will be measured, including iron, transferrin, and vitamin B12, to assess the impact of Roxadustat on anemia. |
| Secondary | Length of Hospital Stay | Discharge or within 4 weeks of hospitalization (whichever comes first) | The total duration of hospitalization for each participant, measured in days. |
| Secondary | Hospitalization Costs | Discharge or within 4 weeks of hospitalization (whichever comes first) | The total cost of the hospital stay for each participant, including all treatments and care. |
| Secondary | Thrombotic Events | From admission to discharge (up to 28 days) and at follow-up visits at 1 and 6 months post-surgery. | Incidence of thrombotic events, including deep vein thrombosis, myocardial infarction, ischemic stroke, and pulmonary embolism. |
| Secondary | Hyperkalemia | From the start of medication until 3 days after the end of treatment. | Occurrence of elevated potassium levels (hyperkalemia) during the perioperative period. |
| Secondary | Metabolic Acidosis | From the start of medication until 3 days after the end of treatment. | Incidence of metabolic acidosis as measured by blood gas analysis. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06772272
GET https://conductscience.org/api/trials/v1/NCT06772272/registered?page=2